U.S. Banks Stock News

Why Old Second Bancorp is back on investors’ radar Old Second Bancorp (OSBC) is attracting attention after several years of strong net interest income growth, linked to its high-yielding loan book and 4.8% net interest margin, which are supporting market share gains. See our latest analysis for Old Second Bancorp. At a share price of $19.78, Old Second Bancorp has seen a 16.01% 90 day share price return, while its 1 year total shareholder return of 16.18% and 5 year total shareholder return...

What recent performance says about Phathom Pharmaceuticals Without a single clear news catalyst, Phathom Pharmaceuticals (PHAT) has still drawn attention after a recent month of modest gains, a stronger move over the past 3 months, and a sharply positive 1 year total return. Those returns sit against a value score of 4 and a share price of about $15.02 at the last close. This has prompted some investors to compare that recent performance with the company’s current fundamentals. See our latest...

Earlier this week, Needham analyst Tom Nikic upgraded Steven Madden from Hold to Buy, citing the company’s positioning to benefit from evolving fashion trends and the integration of recently acquired Kurt Geiger. The upgrade reflects growing analyst confidence that Kurt Geiger could meaningfully enhance Steven Madden’s sales mix and profitability profile over the next few years. We’ll now examine how expectations for margin improvement from the Kurt Geiger acquisition may influence Steven...

Recent performance snapshot for Hanover Insurance Group Hanover Insurance Group (THG) has drawn investor attention after a period where the share price showed a 2% decline over the past week and a 6.3% decline over the past month. Over the past 3 months, the stock shows a 2.5% decline, while the year to date return is down 3.3%. This sits alongside a 1 year total return of 20.2% and a 5 year total return of 63.1%. See our latest analysis for Hanover Insurance Group. Recent share price...

Oculis Holding AG recently announced that the U.S. FDA granted Breakthrough Therapy Designation to its neuroprotective candidate Privosegtor for optic neuritis, supported by positive Phase 2 ACUITY trial data and initiation of the PIONEER registrational program in multiple optic neuropathies. This milestone, alongside the late-stage OCS-01 eye drop program for diabetic macular edema, positions Oculis as an emerging player in high unmet-need neuro-ophthalmic and retinal diseases with...

Falling interest rates and easier lending standards have put Enova International (ENVA) back in focus for investors, as its data driven fintech lending model and shareholder returns come under renewed scrutiny. See our latest analysis for Enova International. At a latest share price of $161.6, Enova’s 30 day share price return of 14.29% and 90 day share price return of 55.37% sit alongside a 1 year total shareholder return of 70.03% and 5 year total shareholder return above 5x. This suggests...

In early January 2026, Appian said it will press ahead with its trade secret lawsuit against Pegasystems after the Virginia Supreme Court sent the case back for retrial and rejected Pegasystems’ bid to have it thrown out, with the court’s opinion describing how Pegasystems allegedly hired a “spy” to obtain Appian information. The continued legal battle, including unresolved trade secret claims and an unchallenged finding under the Virginia Computer Crimes Act, keeps legal risk and potential...

What Perdoceo’s New Buyback Means for Investors Perdoceo Education (PRDO) has put a fresh US$100 million share repurchase program in place, replacing its earlier authorization and running through June 30, 2027, while reaffirming its 2026 adjusted operating income outlook. This combination of a new buyback and unchanged guidance gives investors a concrete update on how management is thinking about capital allocation, earnings quality and the current share price, all using information the...

In December 2025, NRSInsights reported that same-store sales on the National Retail Solutions point-of-sale platform increased 4.5% year over year, while the average price paid for the top 500 items rose 2.3%. This combination of higher volumes and prices points to resilient demand at independent retailers using IDT’s NRS platform, underlining the importance of its data-driven retail ecosystem. Next, we’ll examine how this December same-store sales growth could influence IDT’s existing...

In early January 2026, Rapport Therapeutics announced that the FDA had cleared RAP-219 to enter Phase 3 registrational trials for focal onset seizures and confirmed broader pipeline progress, including bipolar mania, long-acting injectables, and a lifted clinical hold on its diabetic peripheral neuropathic pain trial. This combination of an advanced late-stage epilepsy program and a broadened neurology and pain portfolio highlights Rapport’s effort to build a multi-indication franchise...

This article is for readers wondering whether Star Bulk Carriers still offers value at today’s price or whether most of the opportunity is already reflected in the share price, and is aimed at helping you frame that question clearly. The stock closed at US$19.64, with returns of 1.4% over 7 days, 0.9% over 30 days, 1.4% year to date and 31.0% over the past year, plus 16.3% over 3 years and 199.1% over 5 years. These figures can shape how investors think about both upside and risk...

Enliven Therapeutics (ELVN) shares moved after the company released encouraging initial Phase 1b ENABLE data for ELVN-001 in heavily pretreated chronic myeloid leukemia patients who are relapsed, refractory, or intolerant to existing tyrosine kinase inhibitors. See our latest analysis for Enliven Therapeutics. The latest ENABLE readout arrived alongside a board refresh, with industry veteran Scott Garland joining as a director. The stock has been highly reactive. Enliven Therapeutics has seen...

Kadant recently benefited from a sector-wide rally in industrial names after President Trump called for a proposed US$1.50 trillion defense budget for 2027, prompting investors to reassess companies connected to industrial and defense supply chains. The market’s reaction suggests that while the defense-spending proposal does not fundamentally alter Kadant’s core equipment and aftermarket businesses, it has reinforced investor attention on its exposure to broader industrial investment...

In recent days, Zoom Communications has opened nominations for its Zoom Solopreneur 50 List, while also drawing increased attention from analysts following upward revisions to earnings estimates and a Zacks Rank #1 (Strong Buy) rating based on consistent earnings and revenue outperformance. This combination of an AI-focused small-business grant initiative and improving earnings expectations highlights how Zoom is positioning itself at the intersection of artificial intelligence and...

Cabot Corporation recently signed a multi-year supply agreement with PowerCo SE, a Volkswagen Group battery subsidiary, to provide advanced conductive carbons and dispersions for lithium-ion EV battery electrodes across Europe. This partnership deepens Cabot’s role in the EV battery supply chain, highlighting its specialized materials as an enabler of higher performance next-generation electric vehicles and energy storage systems. We’ll now examine how this PowerCo SE agreement, centered on...

Recent commentary around Copart (CPRT) has focused on rising competition from IAA, backed by RB Global, and the effect on market share, growth momentum, and investor confidence in the company’s premium valuation. See our latest analysis for Copart. Copart’s share price has been choppy, with a 2.02% 1 day share price return and 5.45% 7 day share price return, but a 9.23% 90 day share price decline and 28.41% 1 year total shareholder return decline. These figures suggest momentum has been...

In recent months, Addus HomeCare has expanded through higher service volumes, Medicaid rate increases, and acquisitions including Gentiva personal care assets, Helping Hands, and Del Cielo, while continuing to invest heavily in integration and working capital. This growth push is tempered by ongoing negative free cash flow and the past proposal of about 6.4% Medicare home health payment cuts for 2026, which together highlight the company’s sensitivity to both execution costs and...

Why Northwest Bancshares is on investors’ radar today Northwest Bancshares (NWBI) is drawing attention after recent share price moves, with the stock showing mixed returns over the past week, month, and past 3 months, prompting closer scrutiny of its fundamentals. The regional bank, headquartered in Columbus, Ohio, reports revenue of $564.562 million and net income of $112.97 million, which gives investors concrete figures to compare with its current market valuation. See our latest analysis...

Fortrea Holdings (FTRE) has drawn attention after recent share price moves, with the stock last closing at $17.39. Investors are weighing this pricing against the company’s latest revenue, earnings profile and valuation signals. See our latest analysis for Fortrea Holdings. That recent 30 day share price return of 11.83% sits alongside a much stronger 90 day share price return of 79.74%. However, the 1 year total shareholder return decline of 4.4% suggests that momentum is relatively recent...

Otter Tail (OTTR) just approved a 10% increase in its quarterly dividend to US$0.5775 per share, lifting the annual indicated payout to US$2.31 and extending its 88 year dividend track record. See our latest analysis for Otter Tail. The dividend increase comes as Otter Tail’s share price trades at US$85.61, with a 90 day share price return of 14.07% and a 1 year total shareholder return of 20.54%. This suggests firm but measured momentum following a strong 5 year total shareholder return of...

Westinghouse Air Brake Technologies (WAB) just secured a $386 million follow on order from New York's MTA for additional R255 hybrid battery diesel work locomotives and spare parts, extending deliveries through 2027. See our latest analysis for Westinghouse Air Brake Technologies. The MTA contract lands at a time when Westinghouse Air Brake Technologies' share price has been setting fresh highs, with a 17.48% 90 day share price return and a 19.42% 1 year total shareholder return. This points...

The resolution of Grand Canyon University's non profit status dispute and the expanded stock repurchase authorization are now front and center for Grand Canyon Education (LOPE) investors, helping explain the recent move in the shares. See our latest analysis for Grand Canyon Education. The recent resolution of the university's non profit status and the expanded buyback authorization appear to be feeding into improving sentiment. A 7 day share price return of 6.66% and a 30 day share price...

nCino recently reported an exceptional third quarter, with revenue and next-quarter EPS guidance surpassing analyst expectations, while management emphasized ongoing progress in its AI capabilities. An interesting takeaway is that this strong execution and focus on AI leadership came even as the company’s board approved a US$100,000,000 stock repurchase program, underscoring management’s conviction in nCino’s long-term prospects. We’ll now examine how nCino’s stronger-than-expected quarter...

In recent days, UWM Holdings drew attention as President and CEO Mat Ishbia sold 1.9 million indirectly held shares through SFS Corp, while multiple research firms issued new and updated coverage emphasizing the company’s operational setup and technology initiatives. What stands out is that Ishbia’s transactions are described as part of a derivative conversion and liquidation approach rather than a reduction of his core ownership, occurring alongside fresh analyst commentary on UWM’s...